Author
Listed:
- Kitty B. Murphy
(UK Dementia Research Institute at Imperial College London
Imperial College London
King’s College London)
- Di Hu
(UK Dementia Research Institute at Imperial College London
Imperial College London)
- Leen Wolfs
(VIB
KU Leuven)
- Susan K. Rohde
(VIB
KU Leuven)
- Gonzalo Leguía Fauró
(VIB
University of Antwerp)
- Ivana Geric
(VIB
KU Leuven)
- Renzo Mancuso
(VIB
University of Antwerp)
- Bart Strooper
(VIB
KU Leuven
UK Dementia Research Institute at University College London)
- Sarah J. Marzi
(Imperial College London
King’s College London
UK Dementia Research Institute at King’s College London)
Abstract
Microglia play a key role in the response to amyloid beta in Alzheimer’s disease (AD). In this context, the major transcriptional response of microglia is the upregulation of APOE, the strongest late-onset AD risk gene. Of its three isoforms, APOE2 is thought to be protective, while APOE4 increases AD risk. We hypothesised that the isoforms change gene regulatory patterns that link back to biological function by shaping microglial transcriptomic and chromatin landscapes. We use RNA- and ATAC-sequencing to profile gene expression and chromatin accessibility of human microglia xenotransplantated into the brains of male APPNL-G-F mice. We identify widespread transcriptomic and epigenomic differences which are dependent on APOE genotype and are corroborated across the profiling assays. Our results indicate that impaired microglial proliferation, migration and immune responses may contribute to the increased risk for late-onset AD in APOE4 carriers, while increased phagocytic capabilities and DNA-binding of the vitamin D receptor in APOE2 microglia may contribute to the isoform’s protective role.
Suggested Citation
Kitty B. Murphy & Di Hu & Leen Wolfs & Susan K. Rohde & Gonzalo Leguía Fauró & Ivana Geric & Renzo Mancuso & Bart Strooper & Sarah J. Marzi, 2025.
"The APOE isoforms differentially shape the transcriptomic and epigenomic landscapes of human microglia xenografted into a mouse model of Alzheimer’s disease,"
Nature Communications, Nature, vol. 16(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60099-4
DOI: 10.1038/s41467-025-60099-4
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60099-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.